Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;15(5):321-339.
doi: 10.1080/17446651.2020.1802243. Epub 2020 Aug 19.

Management of patients with persistent or recurrent Cushing's disease after initial pituitary surgery

Affiliations
Review

Management of patients with persistent or recurrent Cushing's disease after initial pituitary surgery

Cristina Capatina et al. Expert Rev Endocrinol Metab. 2020 Sep.

Abstract

Introduction: Treatment options for persistent and recurrent Cushing's disease (CD) include an individualized approach for repeat surgery, medical treatment, radiation therapy (RT), and bilateral adrenalectomy (BLA).

Areas covered: In this expert opinion perspective, the authors review the latest treatment(s) for persistent/recurrent CD. A PubMed search was undertaken (English articles through May 2020) and relevant articles discussed. Repeat pituitary surgery should be considered in most patients with proven hypercortisolism; there is potential for cure with low risk of major complications. Medical therapy is valuable either alone, while awaiting the effects of RT, or in preparation for BLA. Medical therapy includes steroidogenesis inhibitors, agents that act at the pituitary or glucocorticoid receptor level, and novel agents in development. Radiation therapy has been used successfully to treat CD, but hypopituitarism risk and delayed efficacy (improved with radiosurgery) are major drawbacks. Laparoscopic BLA is safe and effective in patients with severe, difficult-to-manage hypercortisolism, but long-term follow-up is required as corticotroph tumor progression can develop.

Expert opinion: Treatment of persistent/recurrent CD is challenging. Most patients require >1 therapy to achieve long-lasting remission. There is currently no ideal single treatment option that provides high and rapid efficacy, low adverse effects, and preserves normal pituitary-adrenal axis function.

Keywords: Cushing’s disease; adrenalectomy; medical therapy; persistence; radiotherapy; recurrence; repeat surgery.

PubMed Disclaimer

Similar articles

Cited by

  • Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
    Feelders RA, Fleseriu M, Kadioglu P, Bex M, González-Devia D, Boguszewski CL, Yavuz DG, Patino H, Pedroncelli AM, Maamari R, Chattopadhyay A, Biller BMK, Pivonello R. Feelders RA, et al. Front Endocrinol (Lausanne). 2023 Oct 9;14:1165681. doi: 10.3389/fendo.2023.1165681. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37876540 Free PMC article. Clinical Trial.
  • New Trends in Treating Cushing's Disease.
    Violetis O, Alexandraki KI. Violetis O, et al. touchREV Endocrinol. 2024 Oct;20(2):10-15. doi: 10.17925/EE.2024.20.2.3. Epub 2024 Apr 8. touchREV Endocrinol. 2024. PMID: 39526050 Free PMC article.
  • Pituitary tumor centers of excellence for Cushing's disease.
    Couselo M, Frara S, Giustina A, Casanueva FF. Couselo M, et al. Pituitary. 2022 Oct;25(5):772-775. doi: 10.1007/s11102-022-01264-6. Epub 2022 Sep 10. Pituitary. 2022. PMID: 36087228 Free PMC article. No abstract available.
  • Cushing's syndrome is associated with altered adipokine profile.
    Dadej D, Szczepanek-Parulska E, Wrotkowska E, Ruchała M. Dadej D, et al. Front Endocrinol (Lausanne). 2022 Dec 6;13:1032329. doi: 10.3389/fendo.2022.1032329. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36561568 Free PMC article.
  • Consensus on diagnosis and management of Cushing's disease: a guideline update.
    Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. Lancet Diabetes Endocrinol. 2021. PMID: 34687601 Free PMC article. Review.

Publication types

Substances

LinkOut - more resources